Sergio Chang Figueroa, MD
Endocrinology, Diabetes & Metabolism · Madisonville, KYNPI 1447498522
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $996,332 of the $1,240,551 with a category attached, or 80.3%. 39 manufacturers reported payments, led by Lilly USA, LLC at 31.6% of the total. Reporting peaked in 2019 at $257,388 and has fallen 56.2% since, to $112,817 in 2025. Among endocrinology, diabetes & metabolism clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,806 payments — averaging $442.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$392K
- Novo Nordisk$288K
- Bayer$228K
- Boehringer Ingelheim$113K
- Abbott$76K
- Sanofi-aventis U.S. LLC$62K
- plus $82K from 33 others
What the payments were for
- Consulting fees$13,6321%
- Speaking & faculty fees$996,33280%
- Travel & lodging$193,26116%
- Food & beverage$37,0363%
- Education$2300%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$225,179
- JARDIANCE$165,465
- RYBELSUS$135,627
- TRULICITY$114,130
- MOUNJARO$108,963
- Ozempic$103,611
- SOLIQUA 100/33$44,832
- FREESTYLE LIBRE 3$37,111
- AFREZZA$34,396
- Tresiba$30,807
- TOUJEO$30,538
- INVOKANA$21,598
- FreeStyle Libre Pro$17,144
- FreeStyle Libre$12,672
- Korlym$11,722
- LYUMJEV$11,550
- Xultophy 100/3.6$6,237
- FreeStyle Libre 2$3,094
- MINIMED 780G$1,671
How this compares
$1,240,551 in reported general payments places this provider in the 95th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
See all endocrinology, diabetes & metabolism providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StrensiqAsfotase Alfa | 13 | $1,814,977 |
| MounjaroTirzepatide | 811 | $968,571 |
| OzempicSemaglutide | 634 | $858,306 |
| JardianceEmpagliflozin | 590 | $563,416 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 321 | $494,099 |
| KerendiaFinerenone | 411 | $422,333 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 441 | $400,352 |
| TrulicityDulaglutide | 208 | $310,559 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 236 | $241,765 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 200 | $186,135 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 164 | $179,912 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 146 | $169,400 |
| Humulin R U-500Insulin Regular, Human | 65 | $149,890 |
| Lyumjev Kwikpen U-200Insulin Lispro-Aabc | 46 | $120,838 |
| Tresiba Flextouch U-200Insulin Degludec | 131 | $116,454 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaStrensiq, Farxiga | $375 | $1,911,431120 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Novolog, Fiasp | $287,970 | $1,558,2171,268 claims |
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog, Baqsimi | $391,568 | $1,382,2671,217 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $112,621 | $779,172831 claims |
| BayerKerendia | $228,189 | $422,333411 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $61,917 | $241,765236 claims |
| Mannkind CorporationAfrezza | $38,208 | $99,24744 claims |
| MerckJanuvia, Janumet Xr | $200 | $57,65959 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
Other endocrinology, diabetes & metabolism in Madisonville
- Bradley EilermanFlorence$1.3M
- Hisham AlrefaiLouisville$720K
- Harold BaysLouisville$214K
- Jahangir CyrusLouisville$155K
- Yancey HolmesCovington$148K
- Moussa AlhajAshland$111K
- Mehdi PoorkayLouisville$81K
- Lyle MyersLexington$60K
- Wendell MiersLexington$38K
- Leera PatelLexington$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.